Disease relevance of BRI3BP

• These 2 proteins colocalized in mitochondria but the expression of HCCR-1 showed negative correlation with that of DP1 in colorectal cancer (CRC) [1].
• HCCR was not only identified in cervical cancer tissues, but also found to be overexpressed in various human malignancies such as leukemia/lymphoma, breast, kidney, stomach, colon, liver and ovarian cancer [2].

High impact information on BRI3BP

• BACKGROUND & AIMS: Human cervical cancer oncogene (HCCR-1) has appeared to act as a negative regulator of p53 and contributes to tumorigenesis of various organs including the colon [1].
• In addition, the level of HCCR-1 was decreased by PI3K inhibitor, LY-294002, in a dose dependent manner [3].
• Northern blot analysis revealed that the HCCR-1 gene expression was down-regulated by LY-294002 [3].
• Expression of phosphatidylinositol 3-kinase (PI3K) in NIH/3T3 cells activated the HCCR-1 promoter [3].
• To determine the regulatory pathway involved in the HCCR-1 gene expression, we searched the 5' flanking region of HCCR-1 and identified HCCR-1 promoter including putative homeodomain protein binding sites [3].

Biological context of BRI3BP

• By RH mapping, the BRI3BP gene was mapped to human chromosome 12q24.2-qter[4]
• Cloning, tissue expression pattern, and chromosome location of a novel human gene BRI3BP [4].
• It was designated as BRI3BP by the HUGO Nomenclature Committee. It contains an open reading frame encoding 251 amino acids [4].
• The level of HCCR-1 expression was increased during the mouse embryogenesis [3].

Analytical, diagnostic and therapeutic context of BRI3BP

• In this paper, we discuss the biological functions of HCCR molecules and its implications for early diagnosis and future development of therapeutic devices of cancer [2].

References